This bill requires the Secretary of Health and Human Services to withdraw the current mifepristone REMS and approve, within 90 days, a risk evaluation and mitigation strategy identical to the one the agency approved in June 2011. It also bars the Secretary from approving any REMS for mifepristone that differs from that 2011 strategy.
Separately, the bill creates a federal tort cause of action against ‘‘covered entities’’—defined to include telehealth providers, pharmacies, and anyone who knowingly imports or transports mifepristone in violation of 18 U.S.C. §1462—and allows compensatory and punitive damages plus attorney’s fees. Finally, it amends the Federal Food, Drug, and Cosmetic Act to prohibit all importation of mifepristone, including by mail.
The measures combine a prescriptive regulatory mandate for FDA with civil and criminal-directional elements that could materially affect telehealth dispensing, cross‑border delivery, and HHS’s regulatory discretion.
At a Glance
What It Does
The bill directs HHS to withdraw the current REMS and reapprove, within 90 days, the exact REMS for mifepristone that was approved in June 2011, and it bars any future REMS that departs from that text. It creates a federal private right of action for physical or mental harm tied to mifepristone that was imported or transported in violation of 18 U.S.C. §1462, and it amends the FDCA to ban importation of mifepristone, including by mail.
Who It Affects
Telehealth providers that prescribe or facilitate out‑of‑state medication abortion, pharmacies that fill mifepristone prescriptions, mail and parcel carriers handling cross‑border shipments, patients seeking medication abortion, and HHS/FDA because the agency must implement a legislatively specified REMS.
Why It Matters
The bill substitutes a Congress‑mandated safety regime for FDA’s discretion, potentially tightening distribution controls and reducing remote access. It also exposes service providers and distributors to federal litigation risk and creates a statutory import ban that directly targets the cross‑border and mail pathways that many patients and providers currently rely on.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill uses three levers to change how mifepristone is regulated and how it moves across state and international lines. First, it defines ‘‘covered medication’’ to mean mifepristone (listed by brand and code name) and tells HHS to withdraw the REMS currently in force and reapprove, within 90 days, the identical REMS that the agency approved in June 2011.
The statute also says the Secretary may not approve any REMS for mifepristone that differs from that 2011 strategy, converting what is normally an agency judgment into a statutory mandate.
Second, the bill creates a federal civil liability regime tied specifically to unlawful importation or transportation. It defines ‘‘covered entity’’ broadly to include telehealth providers, pharmacies, and any person who knowingly moves mifepristone in interstate or foreign commerce in violation of 18 U.S.C. §1462.
An individual who experiences bodily injury or mental‑health harms ‘‘attributable, in whole or in part,’’ to use of such imported medication may sue in federal or state court for compensatory and punitive damages plus attorney’s fees. The provision takes effect 90 days after enactment and says it does not preempt state laws that provide other remedies.Third, the bill amends the Federal Food, Drug, and Cosmetic Act to add explicit language that mifepristone may not be imported into the United States, and it clarifies that mailing mifepristone to individuals is prohibited.
That change plugs the domestic import pathway used by some cross‑border and mail‑order suppliers and creates a statutory basis for enforcement against shipments.Taken together, the bill removes discretionary FDA policymaking from the REMS process for this product, establishes new civil exposure for entities tied to importation or transport, and shuts off the import/mail route as a supply channel. Operationally, HHS would have a hard statutory deadline to act, providers would face new litigation and criminal‑statute triggers, and logistics carriers would have a clearer statutory prohibition to enforce or to defend against in litigation.
The statute also preserves states’ ability to provide additional remedies, so the federal private right of action sits alongside—not instead of—state law options.
The Five Things You Need to Know
Section 3 requires HHS to withdraw the REMS in effect at enactment and approve, within 90 days, a REMS identical to the one approved in June 2011 under 21 U.S.C. §355–1.
Section 3(b) bars the Secretary from approving any REMS for mifepristone that is different from the June 2011 strategy, converting FDA discretion into a statutory constraint.
Section 4 creates a private civil cause of action against a ‘‘covered entity’’ (telehealth provider, pharmacy, or anyone who knowingly imports/transports mifepristone in violation of 18 U.S.C. §1462) for physical or mental‑health harms, allowing compensatory and punitive damages plus attorney’s fees.
Section 4’s liability attaches only where the medication was imported or transported in violation of federal import law (18 U.S.C. §1462), and the section becomes effective 90 days after enactment.
Section 5 amends 21 U.S.C. §381 to state explicitly that no person may import mifepristone into the United States, including by mailing the drug to individuals.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s short name, the 'Restoring Safeguards for Dangerous Abortion Drugs Act.' This is purely nominal but signals the sponsor’s policy framing, which can matter for interpretive statements or legislative history should questions about purpose arise in litigation.
Definition of covered medication
Defines 'covered medication' to mean mifepristone, listing brand names (Mifeprex, Korlym) and the code name RU‑486. That definitional choice pins all downstream obligations, civil liability, and import restrictions to a single, unambiguous product label rather than broader classes of drugs or related compounds.
Mandated REMS reinstatement and prohibition on change
Directs the Secretary to withdraw whatever REMS is active at enactment and to approve within 90 days the exact REMS text that FDA approved in June 2011 under 21 U.S.C. §355–1. Subsection (b) removes agency flexibility by instructing that a REMS is required for mifepristone and that the Secretary may not approve any REMS that differs from the 2011 strategy. Practically, the provision converts a technical regulatory instrument into a piece of statutory command, constraining how FDA can tailor safety controls based on new evidence.
Federal tort liability for harms from unlawfully imported mifepristone
Establishes a federal private right of action for individuals who suffer bodily injury or mental‑health harm linked, even partially, to use of mifepristone that was imported or transported in violation of 18 U.S.C. §1462. It defines covered entities to include telehealth providers and pharmacies and authorizes compensatory and punitive damages plus attorney’s fees. The section takes effect 90 days after enactment and explicitly preserves state laws that provide other remedies, meaning plaintiffs can pursue parallel state claims.
Ban on importation and mailing
Amends 21 U.S.C. §381 to add mifepristone to the framing sentence and inserts a new clause making it unlawful for any person to import mifepristone into the United States, including by mail. That creates a clear statutory bar to cross‑border shipments and gives enforcement agencies and private litigants a textual hook to pursue interdiction or damages tied to mail and import channels.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Plaintiffs alleging harm from unlawfully imported mifepristone — they gain an express federal private right of action that authorizes compensatory and punitive damages and attorney’s fees, widening paths to recovery.
- State attorneys general and private litigators opposing cross‑border medication abortion — the import ban and private cause of action provide additional enforcement and litigation tools against telehealth prescribers and reshippers.
- Domestic manufacturers and distribution channels that comply with the reinstated REMS — they face a regulatory environment that limits competition from certain import or mail channels and may strengthen market advantage for products distributed within the statutory framework.
Who Bears the Cost
- Telehealth providers and out‑of‑state prescribers — they face new litigation exposure and the risk that routine cross‑state dispensing could be characterized as importation or transport in violation of federal law, raising compliance and legal-defense costs.
- Pharmacies and mail/parcel carriers that receive or ship mifepristone — the statutory import ban and the 'knowingly imports or transports' language increase operational risk, potentially forcing tighter screening and refusal of shipments.
- HHS/FDA — the agency must implement a legislatively specified REMS on a 90‑day timetable and loses discretion to modify REMS based on subsequent safety data, increasing administrative and legal burdens.
- Patients seeking medication abortion, especially those relying on mail, telehealth, or cross‑border supply — they risk reduced access and longer supply chains as providers and distributors retrench to avoid liability.
Key Issues
The Core Tension
The central tension is between Congress imposing a hard, prescriptive safety-and‑liability regime to limit distribution of a specific drug and the competing interest in leaving technical safety judgments, balancing of risks, and distribution policy to the FDA and clinical practice; the bill tightens access to reduce perceived harms but does so by removing agency flexibility and by creating legal exposures that may chill legitimate medical and logistical activity.
The bill substitutes a prescriptive statutory command for agency discretion: it does not ask the Secretary to consider evidence and adopt the best available safety regime, it orders an identical reapproval of a specific historical REMS and forbids any departure. That raises separation‑of‑function questions in practice; agencies normally adapt REMS to evolving safety data and post‑market experience.
For providers and distributors, the statute hinges liability on conduct tied to 18 U.S.C. §1462—importation or transport 'in violation' of that criminal statute—creating uncertainties about where routine interstate logistics become a statutory violation and who bears scienter and causation burdens in civil suits.
Operationally, the civil‑liability provision will present litigable issues: how plaintiffs prove that a particular harm is "attributable, in whole or in part" to the drug versus other causes; what proof establishes a defendant 'knowingly' imported or transported the drug in violation of federal law; and whether punitive damages are appropriate where defendants relied on prevailing medical standards or unclear interstate rules. The import ban and mailing prohibition create a bright‑line restriction, but enforcement and defense will raise First Amendment, Commerce Clause, and due process questions in future challenges.
Finally, while the statute preserves state remedies, it could produce duplicative claims and conflicting outcomes where states regulate abortion differently, increasing litigation costs for both defendants and plaintiffs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.